“Financial Overview and Insights: Mineralys Therapeutics Inc. (NASDAQ:MLYS)”
Jefferies analyst sets a promising $30 price target for biopharmaceutical company, Mineralys Therapeutics (NASDAQ:MLYS), predicting a 14.37% surge. MLYS's focus on cardiovascular and renal disease treatments, solid Q4 2025 earnings report and active trading volume positions it as a potentially lucrative investment, despite recent market volatility. Read more
Read More
“VEON Prepares for Earnings Amid Pakistan Spectrum Acquisition”
Global digital operator, VEON Ltd. prepares to release its quarterly earnings, backed by the thriving market position of its subsidiary, Jazz, in Pakistan. With Wall Street analysts projecting an EPS of $1.33 and a revenue close to $1.12 billion, approaching earnings herald a critical financial milestone for VEON. Read more
Read More
“SuRo Capital Corp. (NASDAQ:SSSS) Investment Perspective”
BTIG analyst Marvin Fong predicts a promising future for SuRo Capital Corp, setting a $12.50 price target for NASDAQ:SSSS, a company focused on high growth private investments. This shift in share value forecasts a potential 22% increase, highlighting SuRo Capital's financial success and strategic investments. Keep an eye out for promising returns. Read more
Read More